PRESS RELEASE published on 11/13/2024 at 07:30, 1 year 5 months ago Inside Information / Other news releases GenSight Biologics submits updated LUMEVOQ Dossier to ANSM for early access program restart in France to treat LHON, aiming for first injections in December 2024 GenSight Biologics LHON LUMEVOQ Early Access Program ANSM
BRIEF published on 11/01/2024 at 18:23, 1 year 5 months ago GenSight Biologics Secures €2.8 Million Financing Warrants Financing Gene Therapy GenSight Biologics Retinal Diseases
PRESS RELEASE published on 11/01/2024 at 18:18, 1 year 5 months ago Inside Information / Other news releases GenSight Biologics announces a €2.8 million financing through a Reserved Offering. Funding to extend cash runway for developing gene therapies. Details on investor support and future plans Investors Financing GenSight Biologics Gene Therapies Reserved Offering
BRIEF published on 10/24/2024 at 21:13, 1 year 6 months ago GenSight Biologics Discloses Cash Position, Advances on LUMEVOQ® Treasury Funding LUMEVOQ® ANSM Compassionate Access
PRESS RELEASE published on 10/24/2024 at 21:08, 1 year 6 months ago Inside Information / News release on accounts, results GenSight Biologics reports €3.4 million cash position as of September 30, 2024, updates on LUMEVOQ® drug product status, and financial discussions for future funding Cash Position Financial Update GenSight Biologics LUMEVOQ AAC Resumption
BRIEF published on 10/17/2024 at 07:35, 1 year 6 months ago GenSight Biologics Presents LUMEVOQ® Data at AAO 2024 Gene Therapy GenSight Biologics LUMEVOQ® LHON AAO 2024
PRESS RELEASE published on 10/17/2024 at 07:30, 1 year 6 months ago Inside Information / Other news releases GenSight Biologics to present scientific updates on LUMEVOQ® gene therapy at AAO 2024, including real-world experience and long-term outcomes for LHON patients Gene Therapy GenSight Biologics LHON LUMEVOQ AAO 2024
PRESS RELEASE published on 09/27/2024 at 11:24, 1 year 7 months ago HALF-YEAR_FINANCIAL_REPORT_JUNE_2024
BRIEF published on 09/23/2024 at 19:41, 1 year 7 months ago GenSight Biologics Reports Interim Financial Results for H1 2024 Financial Results Cash Management LUMEVOQ® Early Access Program R&D Expenses
PRESS RELEASE published on 09/23/2024 at 19:36, 1 year 7 months ago Inside Information / News release on accounts, results GenSight Biologics reports interim financial results for the first half of 2024, highlighting optimized cash management, extension of cash runway, and upcoming LUMEVOQ® drug product release Cash Management GenSight Biologics Interim Financial Results LUMEVOQ® Drug Product Release
Published on 04/30/2026 at 23:55, 6 minutes ago Pinetree Capital Announces Unaudited Financial Results for the Period Ended March 31, 2026
Published on 04/30/2026 at 21:00, 3 hours 1 minute ago Datavault AI Schedules Conference Call to Discuss First Quarter 2026 Financial Results on Friday, May 15, 2026
Published on 04/30/2026 at 19:00, 5 hours 1 minute ago Caldwell Announces Appointment of Shawn Banerji as Co-Leader of Technology Practice
Published on 04/30/2026 at 23:39, 21 minutes ago Anemoi International Ltd: Final Results For Year Ended 31 December 2025
Published on 04/30/2026 at 22:35, 1 hour 25 minutes ago Curaleaf Completes Buyout of Remaining Stake in Germany's Four 20 Pharma
Published on 04/30/2026 at 22:04, 1 hour 56 minutes ago Interim individual financial statements for the period ending on March 31, 2026 of Sirma Group Holding JSC
Published on 04/30/2026 at 19:00, 5 hours ago DOUGLAS Group grows sales in Q2 and updates full-year guidance on adjusted EBITDA
Published on 04/30/2026 at 19:00, 5 hours ago BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders
Published on 04/30/2026 at 19:16, 4 hours 44 minutes ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 5 hours 1 minute ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 5 hours 51 minutes ago Minutes of the Combined General Meeting held on April 30, 2026
